JP6194251B2 - 医薬品有効成分およびこれの中間体の酵素的合成 - Google Patents

医薬品有効成分およびこれの中間体の酵素的合成 Download PDF

Info

Publication number
JP6194251B2
JP6194251B2 JP2013545306A JP2013545306A JP6194251B2 JP 6194251 B2 JP6194251 B2 JP 6194251B2 JP 2013545306 A JP2013545306 A JP 2013545306A JP 2013545306 A JP2013545306 A JP 2013545306A JP 6194251 B2 JP6194251 B2 JP 6194251B2
Authority
JP
Japan
Prior art keywords
dehydrogenase
pqq
compound
coli
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013545306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501524A (ja
JP2014501524A5 (enExample
Inventor
ムラク，ペーテル
ゾハール，タデヤ
オスライ，マテイ
コピタル，グレゴール
Original Assignee
レツク・フアーマシユーテイカルズ・デー・デー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10015774A external-priority patent/EP2465936A1/en
Application filed by レツク・フアーマシユーテイカルズ・デー・デー filed Critical レツク・フアーマシユーテイカルズ・デー・デー
Publication of JP2014501524A publication Critical patent/JP2014501524A/ja
Publication of JP2014501524A5 publication Critical patent/JP2014501524A5/ja
Application granted granted Critical
Publication of JP6194251B2 publication Critical patent/JP6194251B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013545306A 2010-12-20 2011-12-20 医薬品有効成分およびこれの中間体の酵素的合成 Expired - Fee Related JP6194251B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10015774.2 2010-12-20
EP10015774A EP2465936A1 (en) 2010-12-20 2010-12-20 Enzymatic synthesis of statins and intermediates thereof
EP11168227 2011-05-31
EP11168227.4 2011-05-31
PCT/EP2011/073412 WO2012095244A2 (en) 2010-12-20 2011-12-20 Enzymatic synthesis of active pharmaceutical ingredient and intermediates thereof

Publications (3)

Publication Number Publication Date
JP2014501524A JP2014501524A (ja) 2014-01-23
JP2014501524A5 JP2014501524A5 (enExample) 2016-06-30
JP6194251B2 true JP6194251B2 (ja) 2017-09-06

Family

ID=45529045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545306A Expired - Fee Related JP6194251B2 (ja) 2010-12-20 2011-12-20 医薬品有効成分およびこれの中間体の酵素的合成

Country Status (7)

Country Link
US (1) US20130337485A1 (enExample)
EP (1) EP2655650B1 (enExample)
JP (1) JP6194251B2 (enExample)
CN (1) CN103403174B (enExample)
AU (1) AU2011355209B2 (enExample)
CA (1) CA2822331A1 (enExample)
WO (1) WO2012095244A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210935A1 (en) * 2009-01-19 2010-07-28 Deinove Methods for isolating bacteria
CN110592249A (zh) * 2019-10-29 2019-12-20 山东省果树研究所 一种快速鉴定果园高效解磷细菌的特异性引物及其试剂盒、分离鉴定方法
CN113373187B (zh) * 2021-05-26 2023-11-10 江苏阿尔法药业股份有限公司 一种氮杂环化合物c27h30fno6的酶催化合成方法
CN114045243B (zh) * 2021-12-03 2023-12-26 山东天力药业有限公司 一种缩短生黑葡萄糖酸杆菌发酵周期的方法
CN116903543A (zh) * 2023-09-08 2023-10-20 重庆普佑生物医药有限公司 一种瑞舒伐他汀钙的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863170A (en) 1973-02-21 1975-01-28 Bendix Corp Thermally stable power amplifier
DE2401055A1 (de) 1974-01-10 1975-07-24 Horst Lindenmann Spielgeraet
US5567605A (en) 1994-11-21 1996-10-22 Uop Assay for D-allose using a NAD cofactor coupled D-allose dehydrogenase
WO2002034919A1 (en) 2000-10-27 2002-05-02 Roche Diagnostics Gmbh Variants of soluble pyrroloquinoline quinone-dependent glucose dehydrogenase
US7414119B2 (en) 2002-09-20 2008-08-19 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
JP4415282B2 (ja) 2003-03-24 2010-02-17 東洋紡績株式会社 基質特異性または安定性に優れたピロロキノリンキノン（ｐｑｑ）依存性グルコースデヒドロゲナーゼ改変体
EP1751287A2 (en) 2004-06-04 2007-02-14 DSMIP Assets B.V. Improved 2-deoxy-d-ribose 5-phosphate aldolases (deras) and the uses thereof
WO2006008132A1 (en) 2004-07-20 2006-01-26 Roche Diagnostics Gmbh Genetically engineered pyrroloquinoline quinone dependent glucose dehydrogenase comprising an amino acid insertion
ES2537106T3 (es) 2004-10-15 2015-06-02 F. Hoffmann-La Roche Ag Mutantes termoestables de la glucosa deshidrogenasa dependiente de quinona de pirroloquinolina
JP2006217811A (ja) 2005-02-08 2006-08-24 Toyobo Co Ltd 基質特異性に優れたピロロキノリンキノン（ｐｑｑ）依存性グルコースデヒドロゲナーゼ改変体
CA2612293A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
EP1969131A1 (en) * 2005-12-15 2008-09-17 Isobionics B.V. Process for the preparation of delta lactones
CA2649135C (en) 2006-04-13 2013-11-19 F. Hoffmann-La Roche Ag Improved mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase
US8183397B2 (en) 2007-04-03 2012-05-22 Lek Pharmaceuticals D.D. Synthesis of statins
US7947483B2 (en) * 2007-08-10 2011-05-24 Genomatica, Inc. Methods and organisms for the growth-coupled production of 1,4-butanediol
US8404870B2 (en) * 2008-01-23 2013-03-26 Lek Pharmaceuticals D.D. ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof
DE102008030435A1 (de) 2008-06-26 2010-01-07 Bayer Technology Services Gmbh Neuartige Varianten PQQ-abhängiger Glukosehydrogenase mit verbesserter Substratspezifität
WO2013068917A1 (en) * 2011-11-07 2013-05-16 Dr. Reddy's Laboratories Limited Processes for the production of a lactone statin intermediate by enzymatic oxidation

Also Published As

Publication number Publication date
JP2014501524A (ja) 2014-01-23
EP2655650A2 (en) 2013-10-30
WO2012095244A2 (en) 2012-07-19
CA2822331A1 (en) 2012-07-19
AU2011355209A1 (en) 2013-07-11
WO2012095244A3 (en) 2012-10-18
US20130337485A1 (en) 2013-12-19
EP2655650B1 (en) 2017-12-20
CN103403174B (zh) 2017-10-27
AU2011355209B2 (en) 2015-09-17
CN103403174A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
US12241112B2 (en) D-glucaric acid producing bacterium, and method for manufacturing D-glucaric acid
US11618906B2 (en) Hydroxylation techniques
Veldmann et al. Bromination of L-tryptophan in a fermentative process with Corynebacterium glutamicum
JP6194251B2 (ja) 医薬品有効成分およびこれの中間体の酵素的合成
Merfort et al. High-yield 5-keto-D-gluconic acid formation is mediated by soluble and membrane-bound gluconate-5-dehydrogenases of Gluconobacter oxydans
Vajdič et al. Engineered, highly productive biosynthesis of artificial, lactonized statin side-chain building blocks: The hidden potential of Escherichia coli unleashed
JP7142813B2 (ja) アミコラトプシス・ルリダ由来シトクロムｐ４５０を用いた分岐状脂肪族または芳香族基質のヒドロキシ化法
Xu et al. Highly efficient synthesis of ethyl (S)-4-chloro-3-hydroxybutanoate by a novel carbonyl reductase from Yarrowia lipolytica and using mannitol or sorbitol as cosubstrate
Venkitasubramanian et al. Aldehyde oxidoreductase as a biocatalyst: reductions of vanillic acid
Griffiths et al. Cloning, isolation and characterization of the Thermotoga maritima KDPG aldolase
Velasco-Lozano et al. Selective oxidation of alkyl and aryl glyceryl monoethers catalysed by an engineered and immobilised glycerol dehydrogenase
Antunes et al. Human xanthine oxidase recombinant in E. coli: A whole cell catalyst for preparative drug metabolite synthesis
Chen et al. Efficient synthesis of Ibrutinib chiral intermediate in high space-time yield by recombinant E. coli co-expressing alcohol dehydrogenase and glucose dehydrogenase
Schweiger et al. Characterization of two aldo–keto reductases from Gluconobacter oxydans 621H capable of regio-and stereoselective α-ketocarbonyl reduction
Schweiger et al. Asymmetric reduction of diketones by two Gluconobacter oxydans oxidoreductases
EP2465936A1 (en) Enzymatic synthesis of statins and intermediates thereof
WO2019013573A2 (ko) 2-히드록시 감마 부티로락톤 또는 2, 4-디히드록시 -부티레이트 의 제조 방법
Li et al. Metabolic engineering of Escherichia coli for the production of glyoxylate from xylose
Chen et al. Efficient synthesis of an ε-hydroxy ester in a space–time yield of 1580 g L− 1 d− 1 by a newly identified reductase RhCR
Abdelraheem et al. Enzymatic cascade of DERA and ADH for lactone synthesis
Asako et al. Biocatalytic reduction system for the production of chiral methyl (R)/(S)-4-bromo-3-hydroxybutyrate
Chen et al. A sialic acid aldolase from Peptoclostridium difficile NAP08 with 4-hydroxy-2-oxo-pentanoate aldolase activity
JP2004236618A (ja) メバロン酸の製造方法及びそれにかかわる酵素遺伝子
Grimm et al. Cyanobacteria as catalysts for light-driven biotransformations
RU2784878C9 (ru) Способ получения 2-оксо-4-валеролактона

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160203

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160510

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170814

R150 Certificate of patent or registration of utility model

Ref document number: 6194251

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees